Cardiac extracellular matrix tenascin-C deposition during fibronectin degradation

Biochemical and Biophysical Research Communications

Volumn 409, Issue 2, 2011, Pages 321-327

  Ma, Shuangtao ^a   Yang, Dachun ^a   Li, De ^a   Tang, Bing ^a   Sun, Meiqin ^a   Yang, Yongjian ^a  

^a General Hospital of PLA Chengdu Military Area Command   (China)

Author keywords

Extracellular matrix; Fibronectin; Matrix metalloproteinases; Myocardial remodeling; Tenascin C

Indexed keywords

ANGIOTENSIN II; FIBRONECTIN; GELATINASE A; GELATINASE B; STROMELYSIN; TENASCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COCULTURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBROBLAST; HEART INFARCTION; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; SHAM PROCEDURE;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; COCULTURE TECHNIQUES; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBRONECTINS; MALE; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; TENASCIN;

EID: 79957928532     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.013     Document Type: Article

References (25)

1. Pieske B. Reverse remodeling in heart failure-fact or fiction?. Eur. Heart J. Suppl. 2004, 6:D66-D78.
2. Milting H., Jacob M., Kassner A., Heimann P., Mannherz H.G., Becker G., Meyer H.E., Bothig D., Arusoglu L., Morshuis M., Korfer R., El Banayosy A. The structural examination of myocardial samples from patients with end-stage heart failure supported by ventricular assist devices using electron microscopy and amino acid analysis reveals low degree of reverse remodeling. J. Heart Lung Transplant. 2004, 23:396-404.
3. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease. J. Clin. Invest. 2007, 117:568-575.
4. Janicki J.S., Brower G.L. The role of myocardial fibrillar collagen in ventricular remodeling and function. J. Card. Fail. 2002, 8:S319-325.
5. Shirwany A., Weber K.T. Extracellular matrix remodeling in hypertensive heart disease. J. Am. Coll. Cardiol. 2006, 48:97-98.
6. Chiquet-Ehrismann R., Chiquet M. Tenascins: regulation and putative functions during pathological stress. J. Pathol. 2003, 200:488-499.
7. Imanaka-Yoshida K., Hiroe M., Nishikawa T., Ishiyama S., Shimojo T., Ohta Y., Sakakura T., Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab. Invest. 2001, 81:1015-1024.
8. Odaka K., Uehara T., Arano Y., Adachi S., Tadokoro H., Yoshida K., Hasegawa H., Imanaka-Yoshida K., Yoshida T., Hiroe M., Irie T., Tanada S., Komuro I. Noninvasive detection of cardiac repair after acute myocardial infarction in rats by 111 In Fab fragment of monoclonal antibody specific for tenascin-C. Int. Heart J. 2008, 49:481-492.
9. Nishioka T., Onishi K., Shimojo N., Nagano Y., Matsusaka H., Ikeuchi M., Ide T., Tsutsui H., Hiroe M., Yoshida T., Imanaka-Yoshida K. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1072-1078.
10. Pat B., Chen Y., Killingsworth C., Gladden J.D., Shi K., Zheng J., Powell P.C., Walcott G., Ahmed M.I., Gupta H., Desai R., Wei C.C., Hase N., Kobayashi T., Sabri A., Granzier H., Denney T., Tillson M., Dillon A.R., Husain A., Dell'italia L.J. Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation. Circulation 2010, 122:1488-1495.
11. Yang D., Ma S., Li D., Tang B., Yang Y. Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium. Biochem. Biophys. Res. Commun. 2009, 388:606-611.
12. Yang D.C., Ma S.T., Tan Y., Chen Y.H., Li D., Tang B., Chen J.S., Su X.H., Li G., Zhang X., Yang Y.J. Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology 2010, 116:133-141.
13. LaFramboise W.A., Scalise D., Stoodley P., Graner S.R., Guthrie R.D., Magovern J.A., Becich M.J. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am. J. Physiol. Cell Physiol. 2007, 292:C1799-1808.
14. Camelliti P., McCulloch A.D., Kohl P. Microstructured cocultures of cardiac myocytes and fibroblasts: a two-dimensional in vitro model of cardiac tissue. Microsc. Microanal. 2005, 11:249-259.
15. Austin B.A., Liu B., Li Z., Nussenblatt R.B. Biologically active fibronectin fragments stimulate release of MCP-1 and catabolic cytokines from murine retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 2009, 50:2896-2902.
16. Ma S., Yang D., Li D., Tang B., Yang Y. Oleic acid induces smooth muscle foam cell formation and enhances atherosclerotic lesion development via CD36. Lipids Health Dis. 2011, 10:53.
17. Ballard V.L., Sharma A., Duignan I., Holm J.M., Chin A., Choi R., Hajjar K.A., Wong S.C., Edelberg J.M. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J. 2006, 20:717-719.
18. Tamura A., Kusachi S., Nogami K., Yamanishi A., Kajikawa Y., Hirohata S., Tsuji T. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart 1996, 75:291-294.
19. Yamamoto K., Dang Q.N., Kennedy S.P., Osathanondh R., Kelly R.A., Lee R.T. Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J. Biol. Chem. 1999, 274:21840-21846.
20. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69:562-573.
21. Feldman A.M., Li Y.Y., McTiernan C.F. Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet 2001, 357:654-655.
22. Ahmed S.H., Clark L.L., Pennington W.R., Webb C.S., Bonnema D.D., Leonardi A.H., McClure C.D., Spinale F.G., Zile M.R. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113:2089-2096.
23. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 2007, 292:C82-C97.
24. Peterson J.T., Hallak H., Johnson L., Li H., O'Brien P.M., Sliskovic D.R., Bocan T.M., Coker M.L., Etoh T., Spinale F.G. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001, 103:2303-2309.
25. Morita H., Khanal S., Rastogi S., Suzuki G., Imai M., Todor A., Sharov V.G., Goldstein S., O'Neill T.P., Sabbah H.N. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H2522-H2527.